Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageWe are a late-stage clinical company dedicated to addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using our proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, we are developing antisense oligonucleotides (“ASOs”) to selectively restore protein levels. Our first investigational, new medicine in development, zorevunersen (STK-001), is a potential disease modifying medicine that is in late-stage clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy.
In the company’s own words · 10-K filed Mar 16, 2026 · SEC EDGAR
Business segments
Q1 2025 · $152.4MThe company’s own SEC segment disclosure.
- IP License$150.8M99%
- Global Development Activity$1.6M1%
Stoke Therapeutics, Inc. (STOK) reported revenue of $6.2M in Q1 2026 (quarter ended March 31, 2026), down 96% from the same quarter a year earlier. That came with net loss of $50M. For the full year FY2025, revenue was $184M (+405% year on year) and net income −$6.9M. Its largest product in 2025-Q1 was IP License at $151M, 99% of the disclosed total, just ahead of Global Development Activity at 1.1%.
Raw charts
8 series · TTMAs reported to the SEC, without any scoring.